EGFR and non-small cell lung carcinoma: Similar findings have been described for patients with EGFR-positive non-small cell lung cancer, where the clonal dominance of EGFR mutations was an independent factor of EGFR tyrosine kinase inhibitor benefit following an analysis of LB, and patients with clonal EGFR mutations exhibited longer PFS [28].